Xylem shares remain flat despite growth and a $1.5B buyback, with better valuation for long-term investors.

Xylem's stock has traded flat over the past year, even as the broader market rose about 20%. The company projects 2–4% organic sales growth and an improved EBITDA margin of 23.1% for the full year, alongside adjusted EPS guidance of $5.35–$5.60. Capital allocation is active, featuring a $1.5 billion share buyback program, a $219 million acquisition in Germany, and a record $850 million order in Water Solutions & Services. Valuation multiples have compressed to 21–22 times earnings, making Xylem more attractive for long-term investors seeking better risk-reward opportunities.